Clinical Trial

Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

Study acronym: CHECK'UP

Terminated

View on ClinicalTrials.gov →

Why the trial stopped

The study was terminated prematurely due to insufficient patient recruitment

Summary

This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.

Protocol Amendment History 3 changes

critical Trial terminated 2026-08-04

critical Trial terminated: The study was terminated prematurely due to insufficient patient recruitment 2026-08-04

notable Enrollment reduced: 670 -> 152 participants 2026-08-04

Trial Details

NCT Number	NCT03412058
Lead Sponsor	UNICANCER Collaborators: Fondation ARC
Conditions	Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Enrollment	152 participants
Start Date	2018-06-27
Primary Completion	2024-01-02 (estimated)
Study Completion	2025-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-03